A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae

Clinical Infectious Diseases

Volumn 33, Issue 4, 2001, Pages 517-522

  Weiss, Karl ^a   Restieri, C ^a   Gauthier, Richard ^a   Laverdieère, Michel ^a   McGeer, Allison ^c   Davidson, Ross J ^b   Kilburn, Laurie ^c   Bast, Darrin J ^c   De Azavedo, Joyce ^c   Low, Donald E ^c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; CHRONIC BRONCHITIS; CLINICAL ARTICLE; FEMALE; GENE MUTATION; HOSPITAL INFECTION; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CROSS INFECTION; DISEASE OUTBREAKS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; FEMALE; FLUOROQUINOLONES; GENOTYPE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PHENOTYPE; PNEUMOCOCCAL INFECTIONS; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 0035882293     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/322658     Document Type: Article

References (34)

1. The epidemiology of respiratory tract pathogens in southern Netherlands
2. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis
3. Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: Ciprofloxacin 750 mg b.i.d. versus clarithromycin 500 mg b.i.d.
4. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
5. Molecular characterization of multidrug resistance in Streptococcus mitis
6. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease
7. An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents
8. Hospital-related outbreak of infection with multidrug-resistant Streptococcus pneumoniae in the Netherlands
9. Clonal relationships among high-level penicillin-resistant Streptococcus pneumoniae in the United States
10. Molecular epidemiology of drug-resistant pneumococci: Toward an international approach
11. Streptococcus pneumoniae carriage in children attending 59 Canadian child care centers
12. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
13. Primary targets of fluoroquinolones in Streptococcus pneumoniae
14. Mutation frequencies and antibiotic resistance
15. Bacterial infection in chronic obstructive pulmonary disease: A study of stable and exacerbated outpatients using the protected specimen brush
16. Expanding uses of fluoroquinolones: Opportunities and challenges
17. Prevalence of antimicrobial resistance in respiratory tract isolates of Streptococcus pneumoniae: Results of a Canadian national surveillance study
18. Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis
19. Inappropriate use of oral ciprofloxacin
20. Infectious complications with respiratory pathogens despite ciprofloxacin therapy
21. Quinolones in the treatment of bronchopulmonary infections
22. Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia
23. Ciprofloxacin concentrations in lung tissue following a single 400 mg intravenous dose
24. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection
25. Fluoroquinolone resistance in Streptococcus pneumoniae
26. Drug-resistant Streptococcus pneumoniae
27. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia
28. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997
29. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
30. Levofloxacin treatment failure of pneumococcal pneumonia and development of resistance during therapy